Breaking Finance News

Intra-Cellular Therapies (NASDAQ:ITCI) has been downgraded from Buy to Neutral in a report by Suntrust Robinson today.

Suntrust Robinson has downgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral in a report released on 9/29/2016.

Previously on 6/2/2016, Piper Jaffray released a statement about Intra-Cellular Therapies (NASDAQ:ITCI) increased the target price from $0.00 to $57.00. At the time, this indicated a possible upside of 0.42%.

Just yesterday Intra-Cellular Therapies (NASDAQ:ITCI) traded -1.17% lower at $42.35. Intra-Cellular Therapies’s 50-day moving average is $40.24 and its 200-day moving average is $37.16. The last stock price is up -58.98% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 5,567,863 shares of ITCI traded hands, up from an average trading volume of 764,584

Recent Performance Chart

Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies has 52 week low of $14.44 and a 52 week high of $59.96 and has a market cap of $0.

In addition to Suntrust Robinson reporting its target price, a total of 8 firms have reported on the stock. The consensus target price is $74.25 with 3 firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *